Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform -- Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ...
KXAN

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
Business Wire

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

- Findings support advancement of ZL-6201 into Investigational New Drug (IND)-enabling studies in 2025 as a potential first-in-class and best-in-class antibody-drug conjugate (ADC) treatment for ...
Seeking Alpha

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) ...
The Victoria Advocate

Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing

We were deliberate in identifying broadly expressed tumor targets where first-generation ADCs have already shown proof of concept. With our next wave ADC portfolio, we aim to build upon these earlier ...
Nasdaq

Sutro Biopharma Prioritizes Next-Generation ADC Programs and Announces Leadership Transition

Sutro Biopharma, Inc. announced a strategic shift focusing on its next-generation exatecan and dual-payload antibody drug conjugate (ADC) programs, deprioritizing the development of luveltamab ...
Business Insider

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format ...
KTLA

DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation

SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation ...